NCT06388616View on ClinicalTrials.gov

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 2, 2024

Primary Completion Date

September 5, 2024

Study Completion Date

September 5, 2024

Conditions
Hepatic Impairment
Interventions
DRUG

Balcinrenone

50 mg, Immediate release capsule to be taken orally.

Trial Locations (3)

32809

Research Site, Orlando

33014

Research Site, Hialeah

78215

Research Site, San Antonio

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT06388616 - Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone | Biotech Hunter | Biotech Hunter